尸体解剖时的激发性血栓 - - 家庭食肉动物血液凝固的第三类
Raluca Elena Tiu1, Raluca Ioana Rizac1, George Laurentiu Nicolae1
1Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine of Bucharest, 011464 Bucharest, Romania.
Life (Basel, Switzerland)
|September 28, 2023
概括
激动性血栓,一种独特的血液凝固形式,发生在死亡过程中,对于诊断动物突然死亡至关重要. 这项研究证实了它的实用性,并描述了它的独特特征.
科学领域:
- 兽医法医病理学 兽医法医病理学
- 心血管病理学心血管病理学
- 血液学 血液学 血液学
背景情况:
- 在兽医法医病理学中,激动性血栓症经常被误诊为死后凝血.
- 区分死期血栓与死后血栓对于准确的死亡原因确定至关重要.
研究的目的:
- 为了确认死角血栓形成是排除突然死亡的重要指标.
- 使用总体,组织学和免疫组织化学方法来表征激发性血栓.
- 为了区分激动性血栓塞与其他凝血事件.
主要方法:
- 对56只家养的食肉动物进行了检查.
- 心脏组织的总体,组织学和免疫组织化学分析.
- 针对CD61 (血小板),纤维原,纤维素,CD45,CD68和·维勒布兰德因子进行免疫组合化学染色.
主要成果:
- 激发性血栓表现出特征性的纤维素排列 (红,网络,波形图案) 和血小板聚合物.
- 对CD61,纤维素原和纤维素的阳性免疫组织化学反应证实了血栓组成.
- 低表达CD45,CD68和·维勒布兰德因子分化激动性血栓.
- 在39.29%的病例中存在心脏病变,这表明与心血管疾病有联系.
结论:
- 激动性血栓代表了鲜明的第三类血凝,仅在激动期形成.
- 绝症性瘤的微观特征类似于最近的真瘤.
- 激发性血栓形成是一种有价值的诊断工具,可以证实死亡前的激发性痛苦.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
741
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
741
Venous Thrombosis I: Introduction
12
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
12
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Coagulation
7.0K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.0K
Extrinsic and Intrinsic Pathways of Hemostasis
8.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


